评估每间隔一天使用帕洛诺司琼的给药方案对多日高剂量化疗中呕吐的控制效果。
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
作者信息
Mirabile Aurora, Celio Luigi, Magni Michele, Bonizzoni Erminio, Gianni Alessandro Massimo, Di Nicola Massimo
机构信息
Department of Medical Oncology, Fondazione IRCCS 'Istituto Nazionale Tumori', Milan, Italy.
出版信息
Future Oncol. 2014 Dec;10(16):2569-78. doi: 10.2217/fon.14.132.
AIM
Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated.
PATIENTS & METHODS: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion).
RESULTS
Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome.
CONCLUSION
Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.
目的
研究间歇性使用帕洛诺司琼对接受多日高剂量化疗（HDC）患者的疗效。
患者与方法
58例患者每隔一天接受一次帕洛诺司琼（0.25mg静脉注射），并每日使用地塞米松（8mg静脉注射，每日两次）。主要终点是整个急性期（化疗结束后24小时内）的完全控制（CC；无呕吐、无需使用抢救性止吐药且仅有轻度恶心）。
结果
接受帕洛诺司琼和昂丹司琼（历史对照队列）治疗的患者在急性期的CC发生率分别为81%和50%。帕洛诺司琼（优势比[OR]：4.37；p = 0.001）和更长疗程的HDC方案（OR：3.47；p = 0.011）独立预测了更好的止吐效果。
结论
每隔一天使用帕洛诺司琼加每日使用地塞米松对接受HDC的患者是一种有效的止吐方案。
Zotero 插件